Quit smoking: effective methods and tobacco-cessation clinics in Morocco

01Smoking in Morocco in figures#

Smoking remains one of the main public health problems in Morocco despite advances in anti-tobacco efforts. According to data from the National Survey on Population and Family Health (ENPSF) 2018 and the National Tobacco Control Programme, approximately 6 million Moroccans smoke, i.e. nearly 13% of the general population. The distribution by sex is particularly marked, reflecting cultural and social factors: 26% of men smoke daily, compared to only 2% of women, but this latter proportion is progressively increasing in young urban women, which constitutes a worrying signal.

The health consequences are considerable. Tobacco is responsible in Morocco for approximately 15,000 annual deaths, equivalent to 40 deaths per day. It causes 80 to 90% of lung cancers, and plays a major role in many other cancers (bladder, larynx, throat, oesophagus, pancreas, kidney, cervix). On the cardiovascular level, tobacco is implicated in approximately 30% of myocardial infarctions occurring before age 60, in a significant proportion of strokes, and in almost all peripheral artery diseases. On the respiratory level, it is the main cause of chronic obstructive pulmonary disease (COPD), a progressive and disabling disease. It also affects fertility, pregnancy (with fetal growth retardation, prematurity, sudden infant death), wound healing, osteoporosis, skin ageing.

A worrying observation is the early age of tobacco initiation. According to surveys by Moroccan anti-tobacco associations, the average age of the first cigarette is around 15 years, sometimes with starts at 12-13 years. Yet the earlier initiation is, the more rapidly and durably dependence sets in, and the more important the long-term health consequences are. Nicotine dependence is one of the fastest to set in among all psychoactive substances — a few days of regular consumption are enough to create physical dependence in adolescents.

The average price of a cigarette pack in Morocco is between 32 and 45 MAD depending on brands, which represents for a one-pack-a-day smoker an annual cost of about 12,000 to 16,000 MAD — a considerable sum that could be devoted to far more useful expenses. Progressive increases in tobacco taxes, recommended by WHO, are one of the most effective measures to reduce consumption, particularly in young people.

A good news: approximately 60% of Moroccan smokers express the wish to quit according to surveys, but only 5 to 10% manage to do so alone, without medical help. The majority of unsupported quit attempts result in relapse within the following weeks or months. This huge gap between motivation and success reveals a major need for structured medical support that can multiply success chances by 5 to 8.

02The remarkable benefits of quitting#

The human body has an extraordinary recovery capacity after smoking cessation, and it is never too late to benefit from it — even a 70-year-old smoker who quits retains tangible benefit on life expectancy and quality of life. Benefits begin from the first hours and continue for several years.

Immediate and short-term benefits

From 20 minutes after the last cigarette, blood pressure and pulse decrease towards normal values. At 8 hours, blood carbon monoxide (CO) levels decrease by half and oxygen levels rise. At 24 hours, CO is completely eliminated from the blood; the bronchi begin to clear smoke residues and some smokers feel a transient increase in cough and expectorations, a paradoxical but positive sign of ongoing pulmonary cleansing. At 48 hours, gustatory and olfactory nerve endings begin to regenerate, taste and smell rapidly improve (smokers often rediscover on this occasion flavours they had lost without realising). From 2 weeks to 3 months, blood circulation significantly improves, walking becomes easier, lung function increases by 30% on average.

Long-term benefits

At 1 year after quitting, the risk of myocardial infarction is halved compared to a smoker. At 5 years, stroke risk joins that of a non-smoker. At 10 years, lung cancer risk is halved compared to a smoker of the same age; risk of other tobacco-related cancers (bladder, throat, oesophagus) also decreases. At 15 years, global cardiovascular risk practically rejoins that of a non-smoker with comparable lifestyle. Life expectancy of a smoker who quits at 30 nearly approaches that of a non-smoker; even quitting at 50 gains an average of 6 years of life expectancy; quitting at 60 still gains 3 years.

Beyond medical figures, daily benefits are numerous: disappearance of morning cough, improved sleep and energy, disappearance of tobacco smell on clothes, in hair, in the house, considerable financial savings, regained freedom from dependence, positive example for children, improved fertility in men and women.

03Scientifically validated methods#

Not all quit methods are equal, and scientific data are now solid to direct smokers towards the most effective approaches. The following table summarises 6-month success rates (continuous abstinence) according to methods used.

The observation is clear: medical help multiplies success chances by 5 to 8 compared to willpower alone. Yet the majority of smokers try to quit alone, which explains the low success rate and repeated relapses that eventually discourage. An essential message to remember: asking for help is not a sign of weakness, on the contrary it is the most rational and effective strategy.

Behavioural support brings specific benefit by helping to identify personal triggers (morning coffee, work break, aperitif, car, stress situations), develop replacement strategies, manage critical periods (first days, first months). Several formats exist: individual consultations with a tobacco-cessation specialist, talking groups between smokers in withdrawal, structured mobile applications (Tabac Info Service, Stop-tabac.ch in French), online support forums.

04Nicotine substitutes#

Nicotine replacement therapy (NRT) delivers to the body the nicotine it depends on, but in a form free of other toxic compounds of cigarette smoke (tar, carbon monoxide, more than 7,000 chemical substances including at least 70 carcinogens). They allow breaking behavioural dependence while avoiding major nicotine withdrawal syndrome. They are available without prescription in pharmacies in Morocco and constitute the first-line option for most smokers wishing to quit.

Several forms are available, ideally to be used in combination to optimise efficacy. Transdermal patches of 24 hours (existing in 7 mg, 14 mg and 21 mg of nicotine) deliver a stable continuous dose of nicotine, to be applied in the morning on a clean and hairless skin area (upper arm, shoulder, hip). Chewing gums (2 mg or 4 mg) are taken at the moment of acute cravings; they must be chewed slowly then kept in the cheek, and avoided with acidic drinks (coffee, juice, sodas) which reduce absorption. Lozenges (1, 2 or 4 mg) are an alternative to gums, to be slowly dissolved in the mouth. The inhaler (cartridges to inhale simulating the smoking gesture) and mouth spray are available on prescription with rapid absorption useful for strong cravings.

The dosage depends on consumption level. A smoker of 10-20 cigarettes per day can start with a 14 mg/24h patch, supplemented if needed with 2 mg gums for acute cravings. A smoker of more than one pack a day must start with a 21 mg/24h patch or even two patches (14+14 or 14+7), associated with 4 mg gums or lozenges. Treatment duration is 8 to 12 weeks minimum with progressive dose reduction (reduce one step every 2 to 3 weeks). Too short a treatment (less than 8 weeks) significantly increases relapse risk. Monthly cost is between 200 and 500 MAD, partially reimbursed by some complementary mutuelles on medical prescription (substitutes are not reimbursed by basic AMO but this situation may evolve).

NRT side effects are generally minor and transient: skin irritation at patch application site (change site daily), digestive disorders (nausea, hiccups) with poorly used gums, vivid dreams with 24h patches (in this case, remove patch at bedtime), sometimes headaches, dry mouth feeling.

05Prescription medications#

For very dependent smokers, or those who failed with NRT alone, several prescription medications can be proposed by the doctor with superior efficacy but some precautions.

Varenicline (marketed under the name Champix) is probably the most effective medication treatment, with a success rate of 30 to 35% at 6 months according to Cochrane meta-analyses. Its mechanism of action is ingenious: it acts as a partial antagonist of brain nicotine receptors, meaning it moderately stimulates these receptors (alleviating withdrawal symptoms) while blocking the effect of inhaled nicotine if the patient smokes (reducing pleasure). Treatment begins 1 week before the set quit date and typically lasts 12 weeks, with possible extension to 24 weeks in case of high relapse risk. Main side effects are nausea (in approximately 30% of patients, generally moderate and transient), vivid dreams, sometimes sleep disturbances, more rarely psychiatric disorders (depressed mood, anxiety — surveillance recommended). Course cost: 800 to 1,200 MAD.

Bupropion (marketed under Zyban in this indication) is an antidepressant whose efficacy in tobacco cessation is demonstrated (success rate 20-25%). It acts on cerebral dopaminergic and noradrenergic pathways. Side effects: dry mouth, insomnia, sometimes headaches, exceptional risk of seizures (hence the formal contraindication in case of epilepsy). It is also contraindicated in case of eating disorders (anorexia, bulimia), cirrhosis, brain tumour.

Cytisine, a natural medication derived from a plant (Cytisus laburnum), is progressively arriving on the European market. Its efficacy is comparable to that of varenicline at significantly lower cost, making it an interesting option for the future.

06Tobacco-cessation consultations in Morocco#

Morocco now has a network of specialised tobacco-cessation consultations that has considerably developed in recent years within the National Tobacco Control Programme.

The public sector, free

Anti-tobacco centres of the Ministry of Health exist in most major cities: Rabat, Casablanca, Fes, Marrakech, Tangier, Agadir, Oujda, Meknes, Tetouan. These centres offer free tobacco-cessation consultations with smoking status assessment, exhaled CO measurement, behavioural support, prescription of NRT or medications according to cases. CHUs and regional hospitals also have specialised consultations: CHU Ibn Rochd in Casablanca (pulmonology service), CHU Ibn Sina in Rabat, CHU Hassan II in Fes, CHU Mohammed VI in Marrakech. Urban and Rural Health Centres often offer first-level consultations with referral to specialist if necessary — free for all AMO beneficiaries and even non-affiliates depending on local policies.

The private sector

Several certified tobacco-cessation doctors practise in private practice in major cities, identifiable by their specific training in tobacco-cessation medicine (DU or equivalent diploma). The fee for a consultation is between 250 and 400 MAD, with reimbursement at 80% by CNOPS, 70% by CNSS, on prescription. Typical follow-up includes 4 to 6 consultations over 3 to 6 months, with telephone interviews between consultations.

Online resources

Several digital tools are available. The Tabac Info Service site (tabac-info-service.fr) offers free resources in French: self-assessment, structured programme, advice, mobile application. The Stop-tabac.ch site is another quality French-language resource. The TabacStop application offers a free virtual personal coach. Support groups on social networks and forums can complement medical support.

07E-cigarettes: for or against?#

The place of the electronic cigarette (e-cigarette, vape) in tobacco cessation remains debated in the scientific community, but the most recent positions of health authorities allow drawing nuanced recommendations. The most recent Cochrane reviews (2024) and Public Health England reports now position the e-cigarette as an effective cessation tool, superior to NRT alone in some studies, and significantly less harmful than traditional cigarettes.

Arguments in favour

The e-cigarette is estimated to be approximately 95% less harmful than combustible tobacco according to Public Health England, due to the absence of combustion and major toxics (tar, carbon monoxide). Its efficacy in cessation is demonstrated in several randomised trials, with a relative risk of success of 1.9 compared to nicotine substitutes. It can be useful for smokers who have failed with other methods, who feel a need to maintain the smoking gesture, or who wish a progressive transition before complete cessation.

Nuances and limits

The e-cigarette is however not harmless. It contains nicotine (addictive substance), sometimes heavy metals from the resistor, flavourings whose long-term respiratory effects are poorly known. Several cases of EVALI (E-cigarette or Vaping product use Associated Lung Injury) have been described, particularly with unregulated products containing vitamin E acetate or THC. Tobacco initiation in adolescents through the e-cigarette is a major concern: studies show that adolescents who vape have an increased risk of subsequently moving to combustible tobacco. Sweet and fruity flavours contribute to attractiveness in young people.

The reasonable position

The e-cigarette should be considered a cessation tool in adult smokers, ideally under medical supervision, with a goal of complete cessation in the long term (ideally within 6 to 12 months). It should in no case be recommended to non-smokers or minors. In Morocco, regulation remains imprecise, with sale of variable-quality products and absence of strict control — established brand products should be preferred and unidentified e-liquids should be avoided. In the long term, the goal remains complete cessation of any nicotine consumption, by progressive withdrawal after a few months of replacement by vape.

08Withdrawal phases and relapses#

Tobacco withdrawal typically follows several phases that are useful to know to better cross them.

The first days are physically the most difficult: nicotine withdrawal symptoms (irritability, anxiety, concentration disturbances, increased appetite, sleep disturbances, intense cravings to smoke every hour). NRT or medications considerably alleviate these symptoms. This phase lasts 3 to 7 days in general.

The first 2 weeks are marked by progressive improvement of physical symptoms, but behavioural dependence takes over: cravings triggered by usual situations (coffee, car, after meals, stress, evening). Identifying and anticipating these triggers is essential.

The first 1 to 3 months are the consolidation period, with cravings progressively spacing out. Many smokers gain a few kilos during this period, which should not be a reason for resumption — regular physical activity and balanced nutrition allow limiting weight gain.

Relapses are frequent and should not be considered a definitive failure. The majority of ex-smokers made several attempts before achieving lasting cessation. Each attempt brings lessons (identified triggers, tested strategies) that increase chances of the next attempt. If you relapse, do not be discouraged: analyse what happened, wait a few weeks to recover motivation, and try again with a more structured approach. The rule is: the more you try, the more you succeed.

Several anti-relapse strategies have proven themselves: maintain medical follow-up for 6 to 12 months after cessation, prolong NRT or medications according to indications (no abrupt cessation), actively manage stress with alternative techniques (sport, meditation, hobbies), avoid very high-risk situations in the first months (drinking parties, conflicts, very close smoking people), celebrate stages (1 week, 1 month, 6 months, 1 year) to maintain motivation, transform savings into concrete rewards to make benefit tangible.